Nautilus Biotechnology, Inc.

Thank you for standing by and welcome to the Nautilus Biotechnology second quarter 2023 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you'll need to press star 1-1 on your telephone. To remove yourself from the queue, simply press star 1-1 again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Carrie Mendeville, Investor Relations.

Thank you. Earlier today, Nautilus released financial results for the quarter ended June 30th, 2023. If you haven't received this news release, or if you'd like to be added to this company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sujil Patel, co-founder and CEO, Bharat Malik, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast, August 2nd, 2023. With that, I'll turn the call over to Sujal.

Thanks, Carrie.